相关实验视频

Updated: Jan 14, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

新生儿败血症中的血小板:凝血之外,从无声的玩家到免疫管弦乐队

Rozeta Sokou¹, Alexandra Lianou², Andreas G Tsantes³

¹Neonatal Department, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece.

Seminars in thrombosis and hemostasis

|October 27, 2025

概括

新生儿血小板在免疫反应和败血症中起着至关重要的作用. 了解它们的独特特性是开发新生儿诊断和治疗策略的关键.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
新生儿科学新生儿科学

背景情况:

血小板传统上与血液静止有关,现在被认为是免疫调节剂.
新生儿的免疫反应是不成熟的,容易发生失调.
与成人血小板相比,新生儿血小板具有不同的特性.

研究的目的:

审查新生儿败血症中的血小板参与.
突出新生儿败血症的免疫和分子特征.
确定新生儿基于血小板的诊断和治疗的研究缺口.

主要方法:

对新生儿败血症中血小板的当前知识的文献综述.
免疫学和分子血小板特征的分析.
确定研究缺口和未来方向.

主要成果:

血小板是生物过程的强大调节者,包括免疫反应.
鲜明的新生儿血小板特性可能会影响炎症反应的敏感性和程度.
目前关于新生儿败血症血小板的知识有限,阻碍了向治疗.

结论:

血小板在新生儿败血症中起着重要的,但尚未研究的作用.
需要进一步的研究来阐明新生儿血小板免疫学,以便在诊断和治疗方面取得进展.
准新生儿血小板有可能改善脆弱婴儿的败血症管理.

更多相关视频

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

相关概念视频

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...